Evidence map›Paper›PMID 34430743›Full record

ArticleHeliyon2021

A seasonal model to assess intervention strategies for preventing periodic recurrence of Lassa fever.

Saumen Barua, Attila Dénes, Mahmoud A Ibrahim

Abstract read
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Modelling Lassa virus dynamics in West AfricanJournal of the Royal Society, Interface · 2024
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Saumen BaruaBolyai Institute, University of Szeged, Aradi vértanúk tere 1., Szeged, 6720, Hungary.
Attila DénesBolyai Institute, University of Szeged, Aradi vértanúk tere 1., Szeged, 6720, Hungary.
Mahmoud A IbrahimBolyai Institute, University of Szeged, Aradi vértanúk tere 1., Szeged, 6720, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lassa haemorrhagic fever is listed in WHO's Blueprint priority list of diseases and pathogens prioritized for research and development, affecting several hundreds of thousands of people each year. Lassa fever is spread via infected Natal multimammate mice and also through human-to-human contacts and it is a particular threat to pregnant women. Despite its importance, relatively few mathematical models have been established for modelling Lassa fever transmission up to now. We establish and study a new compartmental model for Lassa fever transmission including asymptomatic carriers, quarantine and periodic coefficients to model annual weather changes. We determine parameter values providing the best fit to data from Nigerian states Edo and Ondo from 2018-20. We perform uncertainty analysis and PRCC analysis to assess the importance of different parameters and numerical simulations to estimate the possible effects of control measures in eradicating the disease. The results suggest that the most important parameter which might be subject of control measures is death rate of mice, while mouse-to-human and human-to-human transmission rates also significantly influence the number of infected. However, decreasing the latter two parameters seems insufficient to eradicate the disease, while a parallel application of decreasing transmission rates and increasing mouse death rate might be able to stop the epidemic.

Indexed as

Data fittingDisease eradicationLassa haemorrhagic feverPeriodic compartmental model

Identifiers

PMID34430743
PMCPMC8367792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.